Related Experiment Video

Updated: Mar 1, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.0K

Baseline plasma p-tau217/Aβ42 as a sensitive marker for the severity of Alzheimer's disease continuum

Wen-Zheng Liu1,2, Mei Xue3, Ze-Hu Sheng4

  • 1Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, China.

Journal of Translational Medicine
|February 27, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Alzheimer’s diseaseBiomarkerBrain structureCognitive assessmentPlasma p-tau217/Aβ42Predictive performance

More Related Videos

Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure08:40

Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure

Published on: March 21, 2017

8.0K
Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

4.8K

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K